(EXE) Extendicare - Ratings and Ratios
Exchange: TO • Country: Canada • Currency: CAD • Type: Common Stock • ISIN: CA30224T8639
EXE: Long Term Care, Home Health Care, Nursing Services
Extendicare Inc. is a prominent player in the Canadian healthcare sector, specializing in providing a comprehensive range of care and services tailored to the needs of seniors. Through its diverse portfolio of subsidiaries, the company delivers long-term care services, addressing the complex requirements of elderly individuals who require ongoing support and medical attention. Additionally, Extendicare offers an array of home health care services, including skilled nursing care, occupational therapy, physical therapy, speech therapy, and assistance with daily living activities, enabling seniors to maintain their independence and quality of life in the comfort of their own homes.
The company's service offerings extend beyond direct patient care, as it also provides management and consulting services to third-party organizations, leveraging its expertise and experience to enhance the operational efficiency and effectiveness of healthcare providers. Extendicare operates under several distinct brands, including Extendicare, ParaMed, Extendicare Assist, and SGP Purchasing Partner Network, each catering to specific segments of the senior care market. With a history dating back to 1968, Extendicare has established itself as a trusted and reliable partner in the Canadian healthcare landscape, with its headquarters located in Markham, Canada.
As a publicly traded company, Extendicare Inc. is listed under the ISIN code CA30224T8639, with its common stock being a key component of the health care facilities sub-industry within the broader healthcare sector. The company's commitment to delivering high-quality, patient-centered care has earned it a reputation as a leader in the Canadian senior care market, with a strong web presence at https://www.extendicare.com. Through its multifaceted approach to senior care, Extendicare Inc. continues to play a vital role in addressing the evolving needs of Canada's aging population, providing essential services that enhance the well-being and dignity of seniors across the country.
Additional Sources for EXE Stock
EXE Stock Overview
| Market Cap in USD | 638m |
| Sector | Healthcare |
| Industry | Medical Care Facilities |
| GiC Sub-Industry | Health Care Facilities |
| IPO / Inception |
EXE Stock Ratings
| Growth 5y | 108% |
| Fundamental | 66.8% |
| Dividend | 82.3% |
| Rel. Strength Industry | 142 |
| Analysts | - |
| Fair Price Momentum | 21.94 CAD |
| Fair Price DCF | 22.01 CAD |
EXE Dividends
| Dividend Yield 12m | 29.52% |
| Yield on Cost 5y | 676.19% |
| Annual Growth 5y | 43.10% |
| Payout Consistency | 75.2% |
EXE Growth Ratios
| Growth Correlation 3m | 36.8% |
| Growth Correlation 12m | 96.7% |
| Growth Correlation 5y | 98.8% |
| CAGR 5y | 94.03% |
| CAGR/Max DD 5y | 2.36 |
| Sharpe Ratio 12m | 3.01 |
| Alpha | 134.29 |
| Beta | 0.48 |
| Volatility | 30.29% |
| Current Volume | 266.9k |
| Average Volume 20d | 182.5k |
As of February 22, 2025, the stock is trading at CAD 11.45 with a total of 266,906 shares traded.
Over the past week, the price has changed by +2.97%, over one month by +13.35%, over three months by +12.01% and over the past year by +147.06%.
Yes, based on ValueRay Fundamental Analyses, Extendicare (TO:EXE) is currently (February 2025) a good stock to buy. It has a ValueRay Fundamental Rating of 66.75 and therefor a positive outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of EXE as of February 2025 is 21.94. This means that EXE is currently undervalued and has a potential upside of +91.62% (Margin of Safety).
Extendicare has no consensus analysts rating.
According to ValueRays Forecast Model, EXE Extendicare will be worth about 24.9 in February 2026. The stock is currently trading at 11.45. This means that the stock has a potential upside of +117.03%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | 11.4 | -0.4% |
| Analysts Target Price | - | - |
| ValueRay Target Price | 24.9 | 117% |